TI
FULC icon

Trexquant Investment’s Fulcrum Therapeutics FULC Stock Holding History

Trexquant Investment’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-453,529
Closed -$3.48M – 2011
2026
Q1 		$3.48M Buy
453,529
+97,982
+28% +$909K 0.03% 795
2025
Q4 		$4.02M Buy
355,547
+334,532
+1,592% +$3.4M 0.04% 689
2025
Q3 		$193K Buy
+21,015
New +$152K ﹤0.01% 1507
2024
Q3 		– Sell
-70,506
Closed -$437K – 1641
2024
Q2 		$437K Buy
70,506
+23,284
+49% +$176K 0.01% 1288
2024
Q1 		$446K Buy
+47,222
New +$422K 0.01% 1183
2022
Q4 		– Sell
-13,886
Closed -$112K – 1490
2022
Q3 		$112K Buy
+13,886
New +$99.4K ﹤0.01% 1278

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Trexquant Investment's FULC Position: Q2 2026 in Review

Trexquant Investment sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 453,529 shares — an estimated $3.48M sold.

Trexquant Investment first reported a position in FULC in Q3 2022 and held it in 6 quarters. The position peaked at $4.02M in Q4 2025. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Trexquant Investment reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Trexquant Investment sold 453,529 Fulcrum Therapeutics shares in Q2 2026, an estimated $3.48M.
  • Trexquant Investment first reported a position in Fulcrum Therapeutics in Q3 2022 and held it in 6 quarters.
  • Trexquant Investment's Fulcrum Therapeutics position peaked at $4.02M in Q4 2025.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.